CD200R1

23andMe Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
FDA, Research, African Americans, 23andMe, PGS, Health, Science, CORE (research service), Society for Immunotherapy of Cancer, Behavior, BRCA1, Consumer, Genetics, EBITDA, Workforce, Health Action International, Premium, Bangladesh Technical Education Board, Inflammation, BRCA2, DNA, Advertising, Pharmacokinetics, Consumer service, SITC, Science (journal), Immunotherapy, Database, Growth, Marketing, Webcast, GSK, GSK plc, Blood, Society, African, Total, Table, Pharmacogenomics, Harvard University, Lijun International Pharmaceutical (Holding) Co. Ltd., SAN, Pharmaceutical industry, Mobile phone, CD200R1, Simvastatin, Therapy

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second quarter of fiscal year 2024 (FY24), which ended September 30, 2023.
  • Members of Total Health will also receive all the reports and features offered in our existing 23andMe+ Premium Membership.
  • Full year Adjusted EBITDA deficit is reaffirmed to be in the range of $180 to $160 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, November 8, 2023, to discuss the financial results for Q2 FY2024 and report on business progress.

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Retrieved on: 
Monday, November 6, 2023
Society for Immunotherapy of Cancer, MTD, Half-life, PD, Progression-free survival, Clinical research, Genetics, Solar cycle 1, MD, PFS, MSI-H, Primary peritoneal carcinoma, Doctor of Philosophy, Carcinoma, ADA, Neoplasm, Clinical trial, PK, ORR, Safety, Society, Renal cell carcinoma, Therapy, AE, Patient, Helios Techno Holding Co., Ltd., Associate, Vaccine, Pharmaceutical industry, CD200R1, Immunotherapy, Cancer

Updated data from the now completed dose escalation phase continue to showcase the manageable safety profile of 23ME-00610 at the dose levels tested, and highlight preliminary efficacy results in patients with advanced solid tumors.

Key Points: 
  • Updated data from the now completed dose escalation phase continue to showcase the manageable safety profile of 23ME-00610 at the dose levels tested, and highlight preliminary efficacy results in patients with advanced solid tumors.
  • The data was presented in two posters at the Society of Immunotherapy in Cancer Annual Meeting 2023 on Friday, November 3, 2023.
  • The poster presentations are available on the 23andMe Therapeutics and Investor websites.
  • Of the phase 1 patients enrolled across all doses of the dose escalation, there was a 52% stable disease rate.

23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Fubon Financial Holding Co., SITC, Pharmacokinetics, Immunotherapy, Society, Patient, Genetics, SAN, Safety, Annual general meeting, Pharmaceutical industry, CD200R1

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, taking place November 1-5, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA, taking place November 1-5, 2023.
  • The presentations will include updated safety and efficacy data from the Phase 1 portion of the ongoing Phase 1/2a study of 23ME-00610 in patients with advanced solid malignancies.
  • The Company will also present data on the pharmacokinetics, pharmacodynamics and safety data supporting the Phase 1 and Phase 2 dose selection for the 23ME-00610 study.
  • Title: Phase 1/2a Dose Selection of 23ME-00610, a First-in-Class anti-CD200R1 Antibody, in

23andMe Reports FY2024 First Quarter Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Acceleration, FirstBank Holding Co, Database, 23andMe, GSK, Advertising, Interim, Total, Telehealth, Depression, Table, Genetics, Sickle cell trait, Marketing, PRS, Food and Drug Administration, ML, Indigenous, PGS, Lupus, Consumer service, Native Americans, Morehouse School of Medicine, Net, Panic, EBITDA, Patient, Drug discovery, Sickle cell disease, Consumer, Growth, Entrepreneurship, Research, Adjustment, FDA, Food, Genome, Agricultural Research Service, Pharmaceutical industry, Mobile phone, CD200R1, Webcast, Therapy

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports. 23andMe also has the largest crowdsourced platform for advanced genetic research, which enables the Company to deliver ongoing genetic reports, new health features and new risk predictions to customers annually. The platform also accelerates the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas. 23andMe’s platform was built to help people access, understand, and benefit from the human genome.

Key Points: 
  • Webcast at 4:30 pm ET, August 8, 2023
    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, reported its financial results for the first quarter (Q1) of fiscal year 2024 (FY2024), which ended June 30, 2023.
  • 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health reports.
  • “The Company made solid progress this past quarter across both our Therapeutics and Consumer businesses,” said Anne Wojcicki, Co-Founder and CEO of 23andMe.
  • The guidance assumes the following:
    23andMe will host a conference call at 4:30 p.m. Eastern Time today, August 8, 2023 to discuss the financial results for Q1 FY2024 and report on business progress.

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
Thursday, May 25, 2023
Exercise, GSK, Interim, Total, AACR, Obesity, Diet, Therapy, Table, Marketing, Culture, CD200R1, Stroke, Tax, Pharmacokinetics, Research, PGS, Consumer service, Sale, EBITDA, Patient, Risk, Novartis, Webcast, Afkhami, Consumer, ESG, Poster, Growth, Adjustment, Gene, Disease, Safety, Pharmaceutical industry, CORE (research service)

SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the fourth quarter (Q4) and full year of fiscal year 2023 (FY2023), which ended March 31, 2023. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports. The Company has also created the world’s largest, re-contactable crowdsourced platform of genotypic information paired with billions of phenotypic data points contributed by engaged customers. This unique platform enables the Company to discover new genetic insights, develop impactful risk prediction reports for common health conditions, and accelerate the identification of novel drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • The results showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignancies.
  • The Phase 2a portion of the study will further characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profile of 23ME-00610.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 25, 2023 to discuss the financial results for the full year and Q4 FY2023 and report on business progress.
  • A webcast replay will be available at the same address for a limited time within 24 hours after the event.

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Retrieved on: 
Friday, April 14, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., PK, Carcinoma, AACR, PD, Neutrophil, Genetics, Half-life, Progression-free survival, Chills, Pharmacokinetics, American Association for Cancer Research, Itch, Children's Oncology Group, Doctor of Philosophy, Hypothyroidism, PFS, Renal cell carcinoma, Eastern Cooperative Oncology Group, Sarcoma, Primary peritoneal carcinoma, MD, Patient, ECOG, Cancer, AM, MSI-H, Toxicity, Therapy, ORR, Safety, Fatigue, Pharmaceutical industry, Vaccine, CD200R1

23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.

Key Points: 
  • 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.
  • Based on the Phase 1 data, a dose of 23ME-00610 given at 1400 mg intravenously every 3 weeks was selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a (Phase 2a) 23ME-00610 study.
  • Among study participants, most experienced at least 1 treatment related adverse event (TRAE); the majority were Grade 1 or 2.
  • A RP2D of 1400 mg 23ME-00610 was selected for evaluation in the Phase 2a portion of the study.

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
American Association for Cancer Research, Safety, AACR, SAN, Helios Techno Holding Co., Ltd., Patient, Genetics, Pharmacokinetics, Genome, Pharmaceutical industry, CD200R1

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the Phase 1 portion of the Phase 1/2a study of 23ME-00610 has been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held in Orlando, Florida, April 14-19, 2023.
  • The poster presentation will provide data on the safety and tolerability of 23ME-00610, an investigational antibody targeting CD200R1 in patients with advanced solid malignancies, and the rationale for the dose selected for the Phase 2a portion of the study.
  • Additional data on the pharmacodynamics and pharmacokinetics of 23ME-00610 will also be presented.
  • The abstract is embargoed by AACR until April 14, 2023, 12:00 PM ET.

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

Retrieved on: 
Tuesday, February 28, 2023
MSI-H, Safety, Therapy, Doctor of Philosophy, MD, Helios Techno Holding Co., Ltd., CD200, Research, Myelocyte, Patient, Genetics, Progression-free survival, Neoplasm, Carcinoma, ORR, SAN, Renal cell carcinoma, 23andMe, PFS, Cancer, Primary peritoneal carcinoma, Genome, Pharmaceutical industry, Medical imaging, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • The Phase 2a component will include assessment of objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in the expansion cohorts.
  • 23andMe anticipates that it will present an update from the Phase 1 dose escalation portion of the study at a scientific conference this year.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.

23andMe Reports FY2023 Third Quarter Financial Results

Retrieved on: 
Wednesday, February 8, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Genetics, Machine learning, Annual general meeting, Marketing, PGS, Research, Telehealth, Food, American Society of Human Genetics, Food and Drug Administration, Family, Tax, Society, ASH, Squamous cell carcinoma, Advertising, ATM, Marker beacon, Wilms' tumor, Webcast, Society for Immunotherapy of Cancer, Immunotherapy, Genome, Human genetics, CD200R1, Drug development, EBITDA, Ashkenazi Jews, SAN, National Human Genome Research Institute, Clinical trial, Keith Lemon's LemonAid, FDA, Agricultural Research Service, Consumer service, GSK, Asthma, Interim, Growth, ASHG, Johns Hopkins, SITC, NHGRI, Therapy, Simvastatin, Pharmaceutical industry, Central Europe, Adjustment

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2023 (FY2023), which ended December 31, 2022. 23andMe is the only company with multiple U.S. Food and Drug Administration (FDA) authorizations for over-the-counter genetic health risk reports, and in particular the only company the FDA has authorized to provide, without physician involvement, genetic cancer risk reports and medication insights on how individuals may process certain commonly prescribed medications based on their genetics. The Company has also created the world’s largest crowdsourced platform for genetic research, which it is using to pursue drug discovery programs rooted in human genetics across a spectrum of disease areas.

Key Points: 
  • These reports are developed by 23andMe scientists using data and insights gathered from thousands of customers who have consented to participate in our research.
  • “Our fiscal third quarter results reflect solid revenue growth in our consumer business, despite the macro-economic headwinds, and give us confidence to raise our full year financial guidance,” said Joe Selsavage, Interim Chief Financial and Accounting Officer of 23andMe.
  • 23andMe is raising its full year guidance following Q3 FY2023 results.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time on Wednesday, February 8, 2023 to discuss the financial results for Q3 FY2023 and report on business progress.

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, Patient, Neoplasm, Immune tolerance, Research, Sumathi Best Television Current Reporting Award, MSI-H, Therapy, Growth, Maintenance, SAN, PLOS, PLOS Genetics, Genetics, GLOBE, Squamous cell carcinoma, Safety, Pharmacokinetics, Securities Exchange Act of 1934, Poster, Terminology, Nature Genetics, Immunotherapy, Securities Act of 1933, 23andMe, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Cancer, Genome, Helios Techno Holding Co., Ltd., Security (finance), Society, CD200, SITC, MD, Nature, Myelocyte, Primary peritoneal carcinoma, Pharmaceutical industry, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.